To help us deliver the best content to our users, please could you take a moment to answer a few questions? This information is anonymous and for use solely by Hedgehogs.net.
Take surveyNot now
News: Clinical Development News, Sept. 21-25
12 days ago - Dow Jones VentureWire Alert
The following is a list of clinical development news from private and public companies during the week of September 21-25.Private companies:
News: Biocompatibles up on positive trial results
16 days ago - Company News From Hemscott
The medical technology group's shares rose after it issued another encouraging clinical trial update for its novel chemotheraphy-enhancing DC Bead technology.Kam Patel reports...
News: Clinical Development News, Sept. 14-18
21 days ago - Dow Jones VentureWire Alert
The following is a list of clinical development news from private and public companies during the week of September 14-18.Private companies:
News: Via QUANTster: In Confidence / Equity Quantitative Researcher / Purchase, NY / Work with an established team of quantitative researchers to model equity transactions cost, provide...
21 days ago - Financial Recruitment Focus
QUANTster.com:The Quantitative Job Market Daily
News: Six Market Vectors ASX ETFs awarded 4 stars ‘Superior’ rating
35 days ago - ETF Express
ETF Six of Market Vectors’ ASX-listed exchange traded funds have received a 4 star ‘Superior’ rating from SQM Research. The ratings affirm that the ETFs are ...
News: EnzymeBioSystems Product Development Update
48 days ago - PR Newswire: OTC, SmallCap
LAS VEGAS, Aug. 20, 2015 /PRNewswire/ --EnzymeBioSystems (OTCBB: ENZB - News) announces that while it continues its early-stage research to obtain an Investigational New Drug ...
News: Orbus Therapeutics Targets Rare Brain Tumor With $32.5M Series A
51 days ago - Dow Jones VentureWire Alert
Orbus Therapeutics Inc. has raised $32.5 million in Series A financing to run Phase III clinical trials for a drug that might improve survival among patients with a rare brain...
News: Novo helps administer $33m to KalVista
78 days ago - Global Corporate Venturing Articles
The series B funding will help KalVista, a spin-out of Vantia Therapeutics, to advance treatments for diabetes and blood disease to clinical trials.
News: FDA Details Benefit-Risk Analysis in IDE Draft Guidance - Medical Device and Diagnostics Industry
103 days ago - "Performance Attribution" OR "Investment Performance" OR "Blakeney Consulting" OR "Performance Analysis" OR "Risk Analysis" OR "GIPS" OR "attribution analysis" - Google News
FDA Details Benefit-Risk Analysis in IDE Draft GuidanceMedical Device and Diagnostics IndustryThe agency sets out its current thinking on factors that impact decision-making a...
News: VIDEO: Robots struggle to stay on their feet
112 days ago - BBC News - Technology
Some of the best falls from the 2015 Darpa Robotics Challenge.
© Copyright Hedgehogs.net Limited, 2010